News on CXCR4 from BioPortfolio.com http://www.BioPortfolio.com Consolidated CXCR4 news from BioPortfolio.com Tue, 09 Feb 2010 18:38:52 GMT en Brain Cancer - New research on brain cancer from S. Nimmagadda and co-authors summarizedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975568&HITNO=0&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975568&THISHREF=http://c.moreover.com/click/here.pl%3fz2504093934%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3975568&HITNO=0&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3975568&THISHREF=http://c.moreover.com/click/here.pl%3fz2504093934%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-lahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3964101&HITNO=1&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3964101&THISHREF=http://c.moreover.com/click/here.pl%3fz2497990614%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3964101&HITNO=1&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3964101&THISHREF=http://c.moreover.com/click/here.pl%3fz2497990614%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNature: Blockade of X4-Tropic HIV-1 Cellular Entry by GSK812397, a Potent Noncompetitive CXCR4 Receptor Antagonisthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952394&HITNO=2&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952394&THISHREF=http://c.moreover.com/click/here.pl%3fz2490775186%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3952394&HITNO=2&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3952394&THISHREF=http://c.moreover.com/click/here.pl%3fz2490775186%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAAC: Merck Will Not Seek Approval of CCR5 Antagonist Vicriviroc for Treatment-experienced HIV Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3946437&HITNO=3&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3946437&THISHREF=http://c.moreover.com/click/here.pl%3fz2487551579%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3946437&HITNO=3&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3946437&THISHREF=http://c.moreover.com/click/here.pl%3fz2487551579%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHIV and Hepatitis.com: Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Programmehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906524&HITNO=4&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906524&THISHREF=http://c.moreover.com/click/here.pl%3fz2466951543%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906524&HITNO=4&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906524&THISHREF=http://c.moreover.com/click/here.pl%3fz2466951543%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBionity.com: New immune link to inflammation, scarring in Graves diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3908711&HITNO=5&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3908711&THISHREF=http://c.moreover.com/click/here.pl%3fz2467984426%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3908711&HITNO=5&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3908711&THISHREF=http://c.moreover.com/click/here.pl%3fz2467984426%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEndocrine Today: Ablynx Successfully Generates Nanobodies Against An Ion Channel And Announces New Gpcr Programmehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890415&HITNO=6&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890415&THISHREF=http://c.moreover.com/click/here.pl%3fz2459191905%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3890415&HITNO=6&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3890415&THISHREF=http://c.moreover.com/click/here.pl%3fz2459191905%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: CCR5 Antagonist Vicriviroc Demonstrates Greater Efficacy in Patients Identified Using More Sensitive CCR5 Trophttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3891189&HITNO=7&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3891189&THISHREF=http://c.moreover.com/click/here.pl%3fz2459588912%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3891189&HITNO=7&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3891189&THISHREF=http://c.moreover.com/click/here.pl%3fz2459588912%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHIV and Hepatitis.com: Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3891183&HITNO=8&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3891183&THISHREF=http://c.moreover.com/click/here.pl%3fz2459587501%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3891183&HITNO=8&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3891183&THISHREF=http://c.moreover.com/click/here.pl%3fz2459587501%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHIV and Hepatitis.com: Ablynx Successfully Generates Nanobodies(R) Against an Ion Channel and Announces New GPCR Programmehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3889486&HITNO=9&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3889486&THISHREF=http://c.moreover.com/click/here.pl%3fz2458766859%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3889486&HITNO=9&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3889486&THISHREF=http://c.moreover.com/click/here.pl%3fz2458766859%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Ablynx Successfully Generates NanobodiesR Against an Ion Channel and Announces New GPCR Programmehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3888117&HITNO=10&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3888117&THISHREF=http://c.moreover.com/click/here.pl%3fz2458309890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3888117&HITNO=10&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3888117&THISHREF=http://c.moreover.com/click/here.pl%3fz2458309890%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioPortfolio: PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expressionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3872035&HITNO=11&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3872035&THISHREF=http://c.moreover.com/click/here.pl%3fz2449449884%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3872035&HITNO=11&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3872035&THISHREF=http://c.moreover.com/click/here.pl%3fz2449449884%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOncogene Journal: Stem-Cell Transplant and the Prospect for an HIV Curehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3855022&HITNO=12&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3855022&THISHREF=http://c.moreover.com/click/here.pl%3fz2441697438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3855022&HITNO=12&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3855022&THISHREF=http://c.moreover.com/click/here.pl%3fz2441697438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAIDS Clinical Care: TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematolohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3741956&HITNO=13&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3741956&THISHREF=http://c.moreover.com/click/here.pl%3fz2383460404%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3741956&HITNO=13&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3741956&THISHREF=http://c.moreover.com/click/here.pl%3fz2383460404%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematolohttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3741955&HITNO=14&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3741955&THISHREF=http://c.moreover.com/click/here.pl%3fz2383457856%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3741955&HITNO=14&MSIZE=15&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CXCR4&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3741955&THISHREF=http://c.moreover.com/click/here.pl%3fz2383457856%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire: